TABLE 1.

Human Cohort 1 Patient Characteristics (n = 172)

Age, y	63 ± 11
Women	85 (49)
BMI, kg/m2	29 ± 6
FH	73 (42)
Mild or heterozygous FH	71 (41)
Severe or homozygous FH	2 (1)
Plasma profile at baseline (before PCSK9i therapy)
PCSK9, ng/mL	400 ± 173
Total cholesterol, mg/dL	223 ± 65
LDL-C, mg/dL	137 ± 57
HDL-C, mg/dL	54 ± 20
VLDL-C, mg/dL	36 ± 26
Triglycerides, mg/dL	182 ± 110
Medications
Statins	86 (50)
Ezetimibe	118 (69)
Niacin	3 (2)
Fibrate	4 (2)
Bile acid sequestrant	3 (2)
Omega 3 fatty acids	29 (17)
PCSK9i therapy
Alirocumab (75 mg every 2 weeks)	59 (34)
Evolocumab (140 mg every 2 weeks)	113 (66)

Values are mean ± SD or n (%).

BMI = body mass index; FH = familial hypercholesterolemia; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; PCSK9i = proprotein convertase subtilisin/kexin type 9 inhibitory therapy with monoclonal antibodies; VLDL-C = very low-density lipoprotein cholesterol.